Ascendis Pharma A/S vs Travere Therapeutics
ASND and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASND and TVTX compare
Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus 77.1% for Travere Therapeutics).
Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with −7.4% at Travere Therapeutics.
Ascendis Pharma A/S scores higher on the StockData Score (7 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASND | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | – | $4.7B |
| Share price | $251.27 | $50.39 |
| Change, 1 year | 22.1% | 68.1% |
| Change, 5 years | 56.4% | 67.4% |
| Beta (5Y) | 0.77 | 1.14 |
| Employees | 879 | 497 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.0× |
| P/B | – | 194× |
| EV/EBITDA | – | 194× |
| Fair value | – | $5.96 |
| Margin of safety | – | −745% |
| Growth | ||
| Revenue growth (TTM) | 113% (better) | 77.1% |
| Revenue growth, 5Y average | 153% (better) | 19.9% |
| Profitability | ||
| Gross margin | 91.3% | 98.6% (better) |
| Operating margin | 25.4% (better) | −6.8% |
| Net margin | 70.8% (better) | −7.4% |
| Return on equity | – | −152% |
| Financial health | ||
| Net debt / EBITDA | −1.61 | – |
| Interest coverage | 1.3× (better) | −4.3× |
| Current ratio | 2.99 | 4.05 (better) |
| Altman Z-score | – | 2.24 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 112% |
| Held by insiders | 0.83% | 1.6% |
| Insider net buying, 12 months | −$4.7M (better) | −$99.7M |
| Short interest, % of float | – | 13.6% |
Go deeper
- ASND stock overview
- ASND income statement
- ASND valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.